ABHD8 Inhibitors

ABHD8 inhibitors encompass a variety of chemical compounds that target the functional activity of ABHD8, a serine hydrolase implicated in lipid metabolism. The inhibition mechanism is achieved by molecules such as Orlistat and Tetrahydrolipstatin (THL), which are structurally analogous to lipid substrates and act as potent inhibitors of lipases. These compounds are capable of interfering with the active site of ABHD8, thereby attenuating its ability to process lipid molecules. Betulinic acid, another inhibitor, targets lipid metabolism enzymes and can impair ABHD8's serine hydrolase activity, which is essential for the enzyme's metabolic functions. MAFP, a covalent inhibitor, binds to the serine residue of ABHD8's active site, leading to an irreversible loss of enzymatic activity in phospholipid metabolism.

Furthermore, compounds like JW-642, URB597, PF-3845, and JZL195, although initially developed as inhibitors for other enzymes within the lipid metabolism pathways, such as monoacylglycerol lipase and fatty acid amide hydrolase, also manifest inhibitory effects on ABHD8 due to structural similarities in substrate specificity. This cross-reactivity underscores the interconnected nature of lipid metabolic pathways and the potential for indirect inhibition of ABHD8. WWL70 and JZP-430, which inhibit enzymes similar to ABHD8, might also diminish ABHD8 activity, further influencing lipid signaling. Lastly, KT182 and RHC80267, which are designed to inhibit serine hydrolases and diacylglycerol lipase respectively, may also contribute to the downregulation of ABHD8's role in lipid metabolism due to the enzyme's potential involvement in the metabolism of corresponding substrates. These diverse chemical inhibitors collectively demonstrate the feasibility of targeting ABHD8 to influence lipid metabolism at the enzymatic level.